Advances in diagnosis of chronic liver diseases in pediatric patients

Lucija Ruzman1, Ivana Mikolasevic2, Kristina Baraba Dekanic3

  • 1Pediatric Clinic, UHC Rijeka, Istarska 43, 51 000, Rijeka, Croatia. lucija.ruzman@gmail.com.

Insights

Transient elastography (TE) with controlled attenuation parameter (CAP) offers a valuable, non-invasive method for assessing liver damage in children with chronic liver diseases (CLD). Interpretation requires considering patient factors alongside TE results.

Area of Science:

  • Pediatric Hepatology
  • Non-invasive diagnostic tools

Background:

  • Chronic liver diseases (CLD) pose significant challenges in pediatrics.
  • Nonalcoholic fatty liver disease (NAFLD) prevalence is increasing, necessitating effective monitoring.
  • Non-invasive methods for evaluating pediatric liver fibrosis are currently lacking.

Purpose of the Study:

  • To summarize current knowledge on transient elastography (TE) with controlled attenuation parameter (CAP) for CLD in children.
  • To review the utility of TE in pediatric liver disease assessment.

Main Methods:

  • Non-systematic literature search.
  • Databases searched: Ovid MEDLINE, Ovid EMBASE, Google Scholar, Cochrane Library.
  • Focus on studies evaluating TE in the pediatric population.

Main Results:

  • Provides age-dependent normal values for liver stiffness measurements (LSM).
  • Summarizes advantages and disadvantages of TE and CAP.
  • Details the utility of TE for specific pediatric liver diseases.

Conclusions:

  • TE with CAP is a valuable non-invasive tool for liver damage assessment in children.
  • Clinical interpretation of TE results must integrate patient demographics, disease etiology, and laboratory parameters.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
278
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
264
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
206
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
220
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.9K
Chronic Obstructive Pulmonary Disease01:22

Chronic Obstructive Pulmonary Disease

COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
2.4K